Back to home page

Transgene
Innovative immunotherapeutic approaches for fighting cancer and infectious diseases

Transgene Transgene

Transgene, based in Illkirch (near Strasbourg), is listed on the Paris stock exchange (NYSE-Euronext Compartment B). Institut Mérieux has a 55% holding in the company.

Part of the immunotherapy division of Institut Mérieux, Transgene is a biopharmaceutical company dedicated to treating infectious diseases and cancer.

It develops therapeutic vaccines and innovative immunotherapy products based on exclusive technologies for stimulating patient immune systems by using vectors for the expression of tumoral or infectious antigens in target cells.


Four products now in clinical trials


For cancer:

  • a therapeutic vaccine against non-small cell lung cancer (TG 4010). TG 4010 has shown very encouraging results in phase IIb clinical trials, and is now subject to a major agreement with Novartis. The product is due to enter a phase IIb/phase III clinical trial by the end of 2010.
  • a therapeutic candidate using a unique approach combining immunotherapy and targeted chemotherapy to treat hepatocellular carcinomas and colorectal cancers (TG4023). This product is currently in phase I clinical trials.

For infectious diseases:

  • a therapeutic vaccine used to fight against precancerous cervical lesions linked to the human papilloma virus (TG4001/RG3484). This vaccine currently in phase IIb clinical trials was the basis of a partnership for clinical development with Roche
  • a therapeutic vaccine against chronic Hepatitis C (TG4040) that is due to enter phase II clinical trials in 2010

A diversified Technological platform


In addition to its historic MVA based technology, Transgene has developed an important know-how in two other areas: Oncolytics and Monoclonal Antibodies. Two products in preclical development (TG6002 and TG3003) are expected to enter the clinic by the end of 2011, further enriching Transgene’s increasingly diversified product portfolio.



Transgene has a manufacturing unit in compliance with the most demanding international safety standards to produce the products necessary to carry out clinical trials.

Nearly 250 people, including numerous high-level researchers – doctors, pharmacists and engineers – are mobilized in research programs to bring new answers to public health problems for which there are presently no satisfactory solutions.

website link :
http://www.transgene.fr